[go: up one dir, main page]

ATE332127T1 - Verwendung von kreatin oder kreatinanologen zur behandlung von huntington chorea, morbus parkinson und amyotrophen lateralsklerose - Google Patents

Verwendung von kreatin oder kreatinanologen zur behandlung von huntington chorea, morbus parkinson und amyotrophen lateralsklerose

Info

Publication number
ATE332127T1
ATE332127T1 AT95939858T AT95939858T ATE332127T1 AT E332127 T1 ATE332127 T1 AT E332127T1 AT 95939858 T AT95939858 T AT 95939858T AT 95939858 T AT95939858 T AT 95939858T AT E332127 T1 ATE332127 T1 AT E332127T1
Authority
AT
Austria
Prior art keywords
creatine
analogs
disease
compounds
diseases
Prior art date
Application number
AT95939858T
Other languages
English (en)
Inventor
Rima Kaddurah-Daouk
Ghaleb Daouk
M Flint Beal
Original Assignee
Avicena Group Inc
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23315864&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE332127(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Avicena Group Inc, Gen Hospital Corp filed Critical Avicena Group Inc
Application granted granted Critical
Publication of ATE332127T1 publication Critical patent/ATE332127T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT95939858T 1994-11-08 1995-11-07 Verwendung von kreatin oder kreatinanologen zur behandlung von huntington chorea, morbus parkinson und amyotrophen lateralsklerose ATE332127T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33638894A 1994-11-08 1994-11-08

Publications (1)

Publication Number Publication Date
ATE332127T1 true ATE332127T1 (de) 2006-07-15

Family

ID=23315864

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95939858T ATE332127T1 (de) 1994-11-08 1995-11-07 Verwendung von kreatin oder kreatinanologen zur behandlung von huntington chorea, morbus parkinson und amyotrophen lateralsklerose

Country Status (8)

Country Link
US (5) US6706764B2 (de)
EP (3) EP2327404A1 (de)
AT (1) ATE332127T1 (de)
AU (1) AU4151996A (de)
CA (1) CA2235350C (de)
DE (1) DE69535104T2 (de)
ES (1) ES2268696T3 (de)
WO (1) WO1996014063A1 (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69535104T2 (de) * 1994-11-08 2007-02-08 Avicena Group, Inc., Cambridge Verwendung von kreatin oder kreatinanologen zur behandlung von huntington chorea, morbus parkinson und amyotrophen lateralsklerose
CH688760A5 (de) * 1995-04-28 1998-03-13 Synergen Ag Topisches Praeparat zur Foerderung des Muskelaufbaus.
DE19537494C2 (de) * 1995-09-25 1997-10-02 Desitin Arzneimittel Gmbh Kreatin zum Schutz von neuralem Gewebe
US6524611B2 (en) 1996-05-31 2003-02-25 The Howard Foundation Compositions containing creatine and creatinine
US7150880B2 (en) 1996-05-31 2006-12-19 The Original Creatine Patent Co. Ltd. Compositions containing creatine and creatinine and a methyl xanthine
US6274161B1 (en) 1996-05-31 2001-08-14 The Howard Foundation Compositions containing creatine in suspension
GB9611356D0 (en) * 1996-05-31 1996-08-07 Howard Alan N Improvements in or relating to compositions containing Creatine, and other ergogenic compounds
US8128955B2 (en) 1996-05-31 2012-03-06 The Original Creatine Patent Company Food compositions containing creatine
US6168802B1 (en) 1996-05-31 2001-01-02 The Howard Foundation Compositions containing creatine and aloe vera extract
WO1999051097A1 (en) * 1998-04-02 1999-10-14 Avicena Group, Inc. Compositions containing a combination of a creatine compound and a second agent
US20060128671A1 (en) * 1998-04-02 2006-06-15 The General Hospital Corporation Compositions containing a combination of a creatine compound and a second agent
EP1100488B1 (de) * 1998-07-28 2003-04-23 SYNTHES AG Chur Verwendung von kreatinsubstanzen zur behandlung von knochen- und knorpelzellen und geweben
US7915233B1 (en) 1998-08-31 2011-03-29 Wellstat Therapeutics Corporation Compositions and methods for treatment of mitochondrial diseases
US6472378B2 (en) 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
US7807654B2 (en) * 1998-08-31 2010-10-05 Wellstat Therapeutics Corporation Compositions and methods for treatment of mitochondrial diseases
US6242491B1 (en) 1999-06-25 2001-06-05 Rima Kaddurah-Daouk Use of creatine or creatine compounds for skin preservation
WO2001003325A2 (de) * 1999-06-30 2001-01-11 Skw Trostberg Aktiengesellschaft Verwendung von kreatin und/oder kreatin-derivaten zur behandlung von befindlichkeitsstörungen bei frauen
DE19929995B4 (de) 1999-06-30 2004-06-03 Skw Trostberg Ag Verwendung von Kreatin und/oder Kreatin-Derivaten zur Behandlung von Befindlichkeitsstörungen bei Frauen
AU2001247474A1 (en) * 2000-03-16 2001-09-24 The Mclean Hospital Corporation Compounds for the treatment of psychiatric or substance abuse disorders
JP2003531857A (ja) 2000-05-01 2003-10-28 アクセラ・インコーポレーテッド アルツハイマー病およびニューロンの代謝の減少によって引き起こされる他の病気を治療および予防するための中鎖トリグリセリドの使用
US6835750B1 (en) 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
EP1567180A4 (de) * 2002-06-04 2010-03-10 Avicena Group Inc Verfahren zur behandlung von kognitiver dysfunktion durch modulierung des energiestoffwechsels im gehirn
WO2005077040A2 (en) * 2004-02-11 2005-08-25 Rensselaer Polytechnic Institute Compositions and methods for treating amyotrophic lateral sclerosis (als)
WO2006004552A1 (en) * 2004-07-07 2006-01-12 Kampavata Ab Transgenic non-human animal for use in research models for studying parkinson's disease
US7947661B2 (en) * 2004-08-11 2011-05-24 The Mclean Hospital Corporation Compounds for the treatment of marihuana dependence, withdrawal, and usage
US20060052448A1 (en) * 2004-09-04 2006-03-09 Mr. Stanley Antosh Use of methyl pyruvate or methyl pyruvic acid for the treatment of diseases of the nervous system and for protecting a human central nervous system against neuronal degeneration caused by defective intracellular energy production.
US7858599B2 (en) * 2005-12-30 2010-12-28 Hander Robert W Enhancement of urogenital function
EP2001293B9 (de) 2006-04-03 2019-04-17 Accera, Inc. Verwendung ketogener verbindungen zur behandlung altersbedingter gedächtnisschwächen
EP2023718A4 (de) * 2006-05-11 2010-04-21 Avicena Group Inc Kreatinligandverbindungen und anwendungsverfahren dafür
US20070292403A1 (en) * 2006-05-11 2007-12-20 Avicena Group, Inc. Methods of treating a neurological disorder with creatine monohydrate
US20070281995A1 (en) * 2006-06-06 2007-12-06 Xenoport, Inc. Creatine analog prodrugs, compositions and uses thereof
US7683043B2 (en) * 2006-06-06 2010-03-23 Xenoport, Inc. Creatine phosphate analog prodrugs, compositions and uses thereof
US20070281983A1 (en) * 2006-06-06 2007-12-06 Xenoport, Inc. Creatine analog prodrugs, compositions and uses thereof
US20070281910A1 (en) * 2006-06-06 2007-12-06 Xenoport, Inc. Salicyl alcohol creatine phosphate prodrugs, compositions and uses thereof
WO2007146085A2 (en) * 2006-06-06 2007-12-21 Xenoport, Inc. Creatine phosphate prodrugs, compositions and uses thereof
DE102007004781A1 (de) 2007-01-31 2008-08-07 Alzchem Trostberg Gmbh Verwendung von Guanidinoessigsäure(-Salzen) zur Herstellung eines gesundheitsfördernden Mittels
US20090005450A1 (en) * 2007-04-09 2009-01-01 Belinda Tsao Nivaggioli Use of creatine compounds for the treatment of eye disorders
WO2008137137A1 (en) * 2007-05-03 2008-11-13 Avicena Group, Inc. Creatine ascorbyl derivatives and methods of use thereof
DE102007030495A1 (de) 2007-06-30 2009-01-15 Alzchem Trostberg Gmbh Verwendung einer eine Kreatin-Komponente enthaltende Zusammensetzung zur Verbesserung der Gedächtnisleistung, der Merkfähigkeit, des Langzeitgedächtnisses und zur Vorbeugung geistiger Ermüdungszustände
ES2608286T3 (es) 2007-07-31 2017-04-07 Accera, Inc. Uso de ensayos genómicos y compuestos cetogénicos para tratamiento de una función cognitiva reducida
AU2008296012A1 (en) * 2007-09-07 2009-03-12 Gencia Corporation Mitochondrial compositions and uses thereof
DE102007053369A1 (de) 2007-11-09 2009-07-02 Alzchem Trostberg Gmbh Verwendung einer eine Kreatin-Komponente enthaltende Zusammensetzung zur Verbesserung der männlichen Fruchtbarkeit
DE102007062288A1 (de) 2007-12-21 2009-06-25 Alzchem Trostberg Gmbh Kreatin-Zubereitung und Verfahren zu deren Herstellung
US8105809B2 (en) 2008-07-03 2012-01-31 Accera, Inc. Enzymatic synthesis of acetoacetate esters and derivatives
KR101734152B1 (ko) 2008-07-03 2017-05-11 액세라인크 신경계 장애의 치료를 위한 아세토아세테이트의 모노글리세리드 및 유도체
US20100041621A1 (en) * 2008-08-15 2010-02-18 Perry Renshaw Methods and compositions for improving cognitive performance
US8350077B2 (en) 2008-12-24 2013-01-08 Vertex Closed Joint Stock Company Amides of creatine, method of their preparation, and remedy possessing a neuroprotective activity
US20100215707A1 (en) * 2009-02-25 2010-08-26 Mcdonald Thomas Activated creatinine and precursors thereof as antibacterial agents, compositions and products containing such agents and uses thereof
AU2010234206B2 (en) 2009-04-06 2016-10-27 Crearene Ag Hemodialysis and peritoneal dialysis solutions comprising one or more creatine compounds
RU2428414C2 (ru) 2009-11-03 2011-09-10 Закрытое Акционерное Общество "Вертекс" Способ получения амидов креатина
US20130243847A1 (en) * 2010-02-24 2013-09-19 Board Of Regents Of The University Of Nebraska Activated creatinine and precursors thereof as antibacterial agents, compositions and products containing such agents and use thereof
US20130281410A1 (en) * 2010-05-13 2013-10-24 University Of Utah Research Foundation Methods for the treatment of psychiatric disorders
DE102011008016A1 (de) * 2011-01-06 2012-07-12 Johannes F. Coy Schokoladenmasse
CA2849073A1 (en) 2011-09-19 2013-03-28 Gencia Corporation Modified creatine compounds
US9233099B2 (en) 2012-01-11 2016-01-12 University Of Cincinnati Methods of treating cognitive dysfunction by modulating brain energy metabolism
JP2015193582A (ja) * 2014-03-28 2015-11-05 国立大学法人 東京大学 イミダゾールジペプチドを含む剤
EP3194370A4 (de) * 2014-09-03 2018-01-24 Lumos Pharma, Inc. Synthese von cyclokreatin und analoga daraus
US9617230B2 (en) 2014-12-22 2017-04-11 Farmington Pharma Development Creatine prodrugs, compositions and methods of use thereof
US10081605B2 (en) 2015-03-11 2018-09-25 Lumos Pharma, Inc. Synthesis of cyclocreatine and analogs thereof
CA2983151C (en) 2015-04-20 2024-03-05 Vireo Systems, Inc. Compositions and methods for neuroprotection and treatment of neurodegeneration
WO2016176636A1 (en) * 2015-04-30 2016-11-03 Rgenix, Inc. Inhibitors of creatine transport and uses thereof
US20190008812A1 (en) * 2017-07-07 2019-01-10 Washington University Methods for treating microglial dysfunction
AR118403A1 (es) 2017-12-01 2021-10-06 Ultragenyx Pharmaceutical Inc Profármacos de creatina, composiciones y métodos de uso de estos
CN108771668B (zh) * 2018-07-24 2019-10-08 四川九章生物科技有限公司 一种用于治疗肌萎缩性脊髓侧索硬化症的联合用药组合物及其制备方法和用途
KR102141737B1 (ko) * 2018-10-23 2020-08-05 이화여자대학교 산학협력단 크레아틴 및 타우린의 혼합물을 함유하는 우울장애 및 불안장애의 치료용 약학적 조성물

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE58849B1 (en) * 1984-12-18 1993-11-17 Gruenenthal Chemie Use of dipeptide derivatives for the manufacture of medicaments for the treatment of patients with amyotrophic lateral sclerosis
US4871718A (en) * 1987-12-29 1989-10-03 Raymond A. Roncari Composition of matter for increasing intracellular ATP levels and physical performance levels and for increasing the rate of wound repair
US5321030A (en) 1989-02-14 1994-06-14 Amira, Inc. Creatine analogs having antiviral activity
DE69031830T2 (de) * 1989-02-14 1998-09-24 Amira, Inc., Cambridge, Mass. Hemmung der transformation der zellen mit erhöhter purin-metabolischer enzymaktivität
US5324731A (en) 1989-02-14 1994-06-28 Amira, Inc. Method of inhibiting transformation of cells in which purine metabolic enzyme activity is elevated
US5676978A (en) * 1989-02-14 1997-10-14 Amira, Inc. Methods of inhibiting undesirable cell growth using a combination of a cyclocreatine compound and a hyperplastic inhibitory agent
US5091404A (en) 1990-10-05 1992-02-25 Elgebaly Salwa A Method for restoring functionality in muscle tissue
PT100115B (pt) * 1991-02-08 1999-06-30 Cambridge Neuroscience Inc Guanidinas substituidas e seus derivados uteis como moduladores de libertacao de neurotransmissores e ensaios de rastreio para de bloqueadores de libertacao de neurotransmissores
US5741661A (en) * 1991-02-08 1998-04-21 Cambridge Neuroscience, Inc. Substituted guanidines and derivatives thereof as modulators of neurotransmitter release and novel methodology for identifying neurotransmitter release blockers
WO1994016687A1 (en) 1993-01-28 1994-08-04 The Trustees Of The University Of Pennsylvania Use of creatine or analogs for the manufacture of a medicament for inhibiting tumor growth
WO1994017794A1 (en) * 1993-02-03 1994-08-18 Steven Andrew Jennings Blends of glycine derivatives and sugars
US5492930A (en) * 1994-04-25 1996-02-20 Schering Corporation Method and formulation for treating CNS disorders
DE69535104T2 (de) * 1994-11-08 2007-02-08 Avicena Group, Inc., Cambridge Verwendung von kreatin oder kreatinanologen zur behandlung von huntington chorea, morbus parkinson und amyotrophen lateralsklerose
US5676976A (en) * 1995-05-19 1997-10-14 Etex Corporation Synthesis of reactive amorphous calcium phosphates
IT1275434B (it) * 1995-05-19 1997-08-07 Farmila Farma Milano Composizioni farmaceutiche e/o dietetiche ad attivita' antiossidante
AU721190B2 (en) * 1995-10-11 2000-06-29 Avicena Group, Inc. Use of creatine analogues for the treatment of disorders of glucose metabolism
US5998457A (en) * 1995-10-26 1999-12-07 Avicena Group, Inc. Creatine analogues for treatment of obesity
DE19653225A1 (de) * 1996-12-20 1998-06-25 Sueddeutsche Kalkstickstoff Kreatin-pyruvate und Verfahren zu deren Herstellung
DE19707694A1 (de) * 1997-02-26 1998-08-27 Sueddeutsche Kalkstickstoff Kreatin-ascorbate und Verfahren zu deren Herstellung
US5886040A (en) * 1997-06-17 1999-03-23 Amt Labs, Inc. Creatine pyruvate salt with enhanced palatability
US6193973B1 (en) * 1997-08-22 2001-02-27 B. David Tuttle Dietary supplement for boosting energy and increasing muscular strength
US6465018B1 (en) * 1997-08-22 2002-10-15 B. David Tuttle Dietary supplement for increasing energy, strength, and immune function
WO1999021565A1 (en) * 1997-10-24 1999-05-06 Cornell Research Foundation, Inc. Nutritional supplement for cerebral metabolic insufficiencies
WO1999051097A1 (en) * 1998-04-02 1999-10-14 Avicena Group, Inc. Compositions containing a combination of a creatine compound and a second agent
US20060128671A1 (en) * 1998-04-02 2006-06-15 The General Hospital Corporation Compositions containing a combination of a creatine compound and a second agent
US6169115B1 (en) * 1998-05-22 2001-01-02 Rima Kaddurah-Daouk Use of aminoguanidine analogs for the treatment of diseases of the nervous system
US6288124B1 (en) * 1998-05-22 2001-09-11 Rima Kaddurah-Daouk Methods of inhibiting undesirable cell growth using an aminoguanidine compound
US20030013633A1 (en) * 1999-06-07 2003-01-16 Rima Kaddurah-Daouk Use of molecules that modulate an energy related associated state
AU5636300A (en) * 1999-06-25 2001-01-31 Avicena Group, Inc. Use of creatine or creatine analogs for the prevention and treatment of transmissible spongiform encephalopathies
US6242491B1 (en) * 1999-06-25 2001-06-05 Rima Kaddurah-Daouk Use of creatine or creatine compounds for skin preservation
DE19929995B4 (de) * 1999-06-30 2004-06-03 Skw Trostberg Ag Verwendung von Kreatin und/oder Kreatin-Derivaten zur Behandlung von Befindlichkeitsstörungen bei Frauen
DE10032964B4 (de) * 2000-07-06 2017-10-12 Beiersdorf Ag Verwendung von Kreatin in kosmetischen oder dermatologischen Zubereitungen
DE10065478C1 (de) * 2000-12-28 2002-08-29 Sueddeutsche Kalkstickstoff Kreatin/Citronensäure-Verbindung, Verfahren zu ihrer Herstellung und Verwendung
DE10106288A1 (de) * 2001-02-02 2002-09-05 Coty Bv Revitalisierender Wirkkomplex für die Haut
DE10133198A1 (de) * 2001-07-07 2003-01-23 Beiersdorf Ag Kreatin enthaltende kosmetische und dermatologische Zubereitungen zur Behandlung und aktiven Prävention trockener Haut und anderer negativer Veränderungen der physiologischen Homöostase der gesunden Haut
DE10136077A1 (de) * 2001-07-25 2003-02-13 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen mit einer Kombination von Kreatinin und/oder Kreatininderivaten mit Kreatin und/oder seinen Derivaten
US6588124B2 (en) * 2001-08-13 2003-07-08 Ballet Makers, Inc. Ballet shoe sole with gusset
US7608258B2 (en) * 2002-04-13 2009-10-27 Allan Mishra Method for treatment of tendinosis using platelet rich plasma
EP1567180A4 (de) * 2002-06-04 2010-03-10 Avicena Group Inc Verfahren zur behandlung von kognitiver dysfunktion durch modulierung des energiestoffwechsels im gehirn
DE10301632A1 (de) * 2003-01-17 2004-07-29 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an Kreatin, Kreatinin und/oder seinen Derivaten in Kombination mit Sojabohnenkeimextrakten
US7179477B2 (en) * 2003-08-15 2007-02-20 Shyam K Gupta Cosmetic dermabrasion treatment system
DE10355716A1 (de) * 2003-11-26 2005-06-23 Beiersdorf Ag Kosmetische Zubereitungen mit einem Gehalt Kreatin und/oder Kreatinderivaten und/oder Kreatinin und/oderKreatininderivaten und organischen Verdickern
US20060039887A1 (en) * 2004-08-20 2006-02-23 Infinity2 Health Sciences, Inc. Cosmetic or pharmaceutical composition for skin care

Also Published As

Publication number Publication date
EP1719510A1 (de) 2006-11-08
US20100303840A1 (en) 2010-12-02
US6706764B2 (en) 2004-03-16
EP0804183B1 (de) 2006-07-05
CA2235350C (en) 2009-01-06
CA2235350A1 (en) 1996-05-17
AU4151996A (en) 1996-05-31
EP0804183A1 (de) 1997-11-05
EP2327404A1 (de) 2011-06-01
ES2268696T3 (es) 2007-03-16
US7285573B2 (en) 2007-10-23
DE69535104T2 (de) 2007-02-08
DE69535104D1 (de) 2006-08-17
WO1996014063A1 (en) 1996-05-17
US20080119450A1 (en) 2008-05-22
US20040106680A1 (en) 2004-06-03
US20040102419A1 (en) 2004-05-27
US20020161049A1 (en) 2002-10-31

Similar Documents

Publication Publication Date Title
ATE332127T1 (de) Verwendung von kreatin oder kreatinanologen zur behandlung von huntington chorea, morbus parkinson und amyotrophen lateralsklerose
DE69530418D1 (de) Formulierungen und verfahren zur verminderung von hautirritationen
ATE196142T1 (de) Vervendung von k-252a derivaten zur förderung der funktion eines stritialen neurons
EP1039887A4 (de) Verfahren zur behandlung von nerven- und nieren-erkrankungen und der arzneimitteltoxizität mit aminothiolverbindungen
ATE121939T1 (de) Ascorbinsäure-tocopheryl-phosphatdiester zur hemmung der maillard-reaktion.
DE69629578D1 (de) Verwendung von wenigstens einem no-synthase hemmer zur behandlung empfindlicher haut
BR9809115A (pt) Métodos para tratar inflamação e doenças inflamatórias usando inibidores de padprt
DE69332641D1 (de) Anabasein derivate zur behandlung von degenerativen erkrankungen des nervensystems
LV10048A (lv) Lidzeklis slimibu arstesanai un ta iegusanas process
ATE309794T1 (de) Methode zur hemmung des wachstums von bakterien oder pilzen mit einem komplexbildner
DE69328771D1 (de) Verfahren zur hemmung der karzinogenese durch behandlung mit dehydroepiandrosteron und dessen analoge
FR2562539B1 (fr) Nouveaux derives de l'acide vinyl-4 benzoique, leur procede de preparation et leurs applications en therapeutique et comme ligands
PT723540E (pt) Compostos triciclicos de amida e ureia uteis para inibicao da funcao da g-proteina e para o tratamento de doencas proliferativas.
ATE188377T1 (de) Chinoline oder chinazolin-derivate und deren verwendung zur herstellung eines medikaments für die behandlung von osteoporose
EP0616032A3 (de) Verbeugende oder therapeutische Mittel für die Alzheimer-Krankheit, eine Siebtest-Methode, und die menschliche Tau-Protein-Kinase.
DE69533842D1 (de) Formulierungen und verfahren zur verminderung von hautirritationen
BR0009378A (pt) Métodos de tratamento de leucemia
ATE184483T1 (de) Spirooxathiolan-quinuclidin-derivat zur behandlung des sjögren-syndroms
GR3035957T3 (en) Use of riluzole for treating aids-related neural disorders
NO960974L (no) Farmasöytisk preparat for behandling av synsnerveforstyrrelse med prostansyreforbindelser
DE69125216D1 (de) Aminoalkanesulfonsäurederivate und pharmazeutische Zusammensetzungen davon zur Prävention oder Behandlung von Herzerkrankungen
BR0009296A (pt) Composição farmacêutica, processos para induzirpromoção de diferenciação de células neurais decélulas-alvo, para promover atividade neural emum indivìduo, e para prevenção ou tratamento dedistúrbios e doenças que podem ser prevenidos outratados por meio de promoção de diferenciaçãode células neurais e/ou de atividade neural, e, usode um composto
KR950031085A (ko) 표피증식 질환 치료용 의약 조성물
DE69331546D1 (de) Verwendung von cytochrome - p 450 - inhibitoren zur hemmung des stoffwechsels von stickstoffsubstituierten acridinen
BR9505842A (pt) Composição inibidora de 5-lipoxigenase,composição para o tratamento de uma doença causada por leucotrienos e método de tratamento de um paciente

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties